retatrutide for diabetes type 2 30mg ESC 2024: Retatrutide improves lipid
Description
This review summarizes recent advances in the anti-inflammatory properties of GLP-1 receptor activation in the brain
The steady-state 24-hour urinary glucose excretion in patients with type 2 diabetes mellitus and mild, moderate, and severe renal impairment was 42%, 80%, and 90% lower, respectively, than in patients with type 2 diabetes mellitus with normal renal function
Approval could come 6-12 months after US approval (late 2027 or 2028)
Any cloudiness suggests protein aggregation, where degraded peptide molecules clump together
GLP-1 : Does It Really Work
